Trial intelligence / Profile preview

Clinical Evaluation of NK211 for Ovarian Cancer (Clinical Pharmacological Study)

jRCT2080220962Phase 1

Sponsor
Nippon Kayaku Co., Ltd.
Start
Jan 2010
Modality
Small Molecules, Nanoparticles → Drug Delivery Systems
Countries
1
01

Overview

Phase 1, open-label, single-arm trial of NK211 in ovarian cancer, sponsored by Nippon Kayaku Co., Ltd.

02

Drugs

NK211
03

Conditions

ovarian cancer

Beyond the preview

Go deeper on jRCT2080220962.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2080220962.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call